The present invention relates to pharmaceutical compositions containing dopaminereceptor ligands and selective serotonin reuptake inhibitors and to methodsof treating disorders such as schizophrenia, major depressive disorder andbipolar depression using combinations of dopamine receptor ligands and selectiveserotonin reuptake inhibitors. The present invention also relates to methodsof treating depression using dopamine receptor ligands.